Therefore, a pharmacological increase in miR-34a expression represents a treatment option for cSCC patients that allows not only to target know proteins regulated by miR-34a but also a reconstitution of NLRP1 expression. This evidence concerns the gene NLRP1 and skin squamous cell carcinoma.